Evidence map›Paper›PMID 42057320›Full record

ArticleJournal of surgical oncology2026

De-Escalating Surgery for 1-2 cm Appendiceal Neuroendocrine Tumors: A North American Multi-Center Analysis.

Richard Max Miller, Po Hong Tan, Andrew Saleeb, Emily R Thompson, Zhi Ven Fong, Chee-Chee Stucky, Sanjay P Bagaria, Emmanuel M Gabriel, Travis E Grotz, Nabil Wasif

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Richard Max MillerDepartment of Surgery, Mayo Clinic, Phoenix, Arizona, USA.ORCID https://orcid.org/0000-0002-4936-2243
Po Hong TanDepartment of Surgery, Mayo Clinic, Phoenix, Arizona, USA.
Andrew SaleebDepartment of Surgery, Mayo Clinic, Phoenix, Arizona, USA.
Emily R ThompsonDepartment of Surgery, Mayo Clinic, Phoenix, Arizona, USA.
Zhi Ven FongDepartment of Surgery, Mayo Clinic, Phoenix, Arizona, USA.
Chee-Chee StuckyDepartment of Surgery, Mayo Clinic, Phoenix, Arizona, USA.
Sanjay P BagariaDepartment of Surgery, Mayo Clinic, Jacksonville, Florida, USA.
Emmanuel M GabrielDepartment of Surgery, Mayo Clinic, Jacksonville, Florida, USA.
Travis E GrotzDepartment of Surgery, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-7753-097X
Nabil WasifDepartment of Surgery, Mayo Clinic, Phoenix, Arizona, USA.

Funding

Mayo Clinic Arizona Department of Surgery
6 · The paper itself

Abstract

BACKGROUND AND

objectivesNCCN guidelines recommend right hemicolectomy (RHC) for appendiceal neuroendocrine tumors (aNETs) > 2 cm and observation for < 1 cm. However, optimal surgical management of 1-2 cm tumors remains controversial. This study compared long-term survival and recurrence between patients undergoing RHC versus appendectomy (APY) for 1-2 cm aNETs.

methodsPatients with pathologically confirmed 1-2 cm aNETs treated at three Mayo Clinic sites (1972-2024) were included. Primary outcomes were recurrence and all-cause mortality after resection. Associations with lymph node (LN) metastasis were assessed in patients with lymphadenectomy.

resultsSixty-five patients were identified: 29 (45%) underwent APY, 35 (54%) RHC, and one ileocecectomy. Median age at diagnosis was 39 years; 71% were female and 94% white. LN positivity was 15.2% for tumors with nodes examined. Tumor size > 1.5 cm, stage T3/T4, and lymphovascular invasion were not associated with nodal metastasis. No survival differences were observed between APY and RHC. LN positivity did not impact survival. No recurrences occurred during a median follow-up of 6.25 years (IQR 2.44-12.63).

conclusionsAmong patients with 1-2 cm aNETs, RHC conferred no survival benefit over APY. Absence of recurrence and the limited prognostic value of nodal disease suggest APY alone may suffice for this population.

Indexed as

AppendectomyAppendiceal NeoplasmsColectomyNeuroendocrine TumorsAdultFemaleFollow-Up StudiesHumansLymphatic MetastasisLymph Node ExcisionMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesSurvival Rateappendectomyappendiceal neuroendocrine tumorsappendix cancerENETS guidelinesNCCN guidelinesright hemicolectomy

Identifiers

PMID42057320
PMCPMC13378785

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.